A Randomized Phase III Study Comparing CHOP Versus CEOP-induced Cardiotoxicity in Patients With Aggressive B-cell Lymphoma
The doxorucin-containing regimen (CHOP) and epirubicin-containing regimen (CEOP) are both
frequently used in patients with aggress B-cell lymphoma in out institution. According to a
Cochrane meta-analysis, epirubicin is less cardiotoxic than doxorubicin on a mg per mg
basis. However, compared with 50mg/m2 of doxorubicin in CHOP, epirubicin was usually used at
a higher dose (70mg/m2) to treat non-Hodgkin's lymphoma (NHL). Because of the correlation
between cumulative dose and risk of cardiotoxicity, it is reasonable to speculate that CEOP
(70mg/m2) has less cardiotoxicity than CHOP (50mg/m2) when both regimens are administered
with similar cycles.
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cardiotoxicity (Class III or IV cardiotoxicity according to New York Heart Association (NYHA) Classification or LVEF abnormality [< 50% or a decrease in absolute LVEF ≥ 10%) by post-treatment RNA])
18 weeks
Yes
Ye Guo, MD
Principal Investigator
Fudan University
China: Ethics Committee
LMTG 09-01
NCT00854568
March 2009
December 2012
Name | Location |
---|